Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Vinod Ravi , Andrew Scott Brohl , Sant P. Chawla , Steven Attia , Richard F. Riedel , David A. Liebner , Katherine Anne Thornton , Atrayee Basu Mallick , Darren W. Davis , Mario Cervantes , Wen Liu , Keyi Zhu , Delia Alvarez , Charles P. Theuer , Steven Ian Robinson , Nicolas Penel , Silvia Stacchiotti , William D. Tap , Robin Lewis Jones , Robert G. Maki
Background: Endoglin (CD105) is an essential angiogenic receptor expressed on Angiosarcoma (AS) tumor cells and vessels that is upregulated following hypoxia and promotes resistance to VEGF inhibition. TRC105, an endoglin antibody, combined with pazopanib (P) achieved durable complete responses in AS patients, with encouraging median PFS of 7.8 months in chemotherapy-refractory and P-naïve patients enrolled in a Phase 1/2 trial. Here we report the capture of endoglin expressing circulating tumor cells (CTCs) using ApoStream dielectrophoresis field flow assist from the whole blood of AS patients enrolled in the ongoing Phase 3 TAPPAS trial. Methods: AS CTCs were enriched by ApoStream from samples drawn prior to treatment, with either TRC105/P or single agent P, at C1D1 and 6 weeks following initiation of study treatment at C3D1. CTCs that expressed CD105 and DAPI (nucleus) by immunofluorescence that used a non-competing endoglin antibody were quantified. CD105+/DAPI+ CTCs were further characterized as atypical cells using Diff-Kwik staining. Results: Forty (40) blood samples (25 at C1D1, 15 at C3D1) from 28 patients were analyzed. Paired pre- and post-treatment samples were available for 13 patients. Endoglin+ CTCs were detected in 100% (40/40) of samples (median = 1.5/mL; range 0.13 - 1,172/ml). Endoglin+ CTCs decreased between C1D1 and C3D1 in 13 patients with paired samples treated with TRC105/P or single agent P (C1D1 mean = 184.3/ml; median = 1.5/ml; range 0.13 - 1172/ml); C3D1 mean = 6.39/ml; median = 0.88/ml; range 0.44 - 26/ml). Diff-Kwik staining confirmed the enriched CTCs had atypical morphology containing hemosiderin deposits and large irregularly shaped nuclei in all cases. Conclusions: ApoStream technology isolated endoglin+ CTCs from the whole blood of AS patients. Decreases in endoglin+ CTCs were observed following treatment with TRC105/P and/or single agent P. Clinical trial information: NCT02979899
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2018 ASCO Annual Meeting
First Author: Vinod Ravi
2017 ASCO Annual Meeting
First Author: Robin Lewis Jones
2015 ASCO Annual Meeting
First Author: Steven Attia
2024 ASCO Genitourinary Cancers Symposium
First Author: Neal D. Shore